Chandigarh based Venus Remedies Limited, a leading research based global pharmaceutical company and injectables manufacturers in the world, launched a novel formulation "ACHNIL" brand of "Aceclofenac- injection" in India. "ACHNIL" injection is a "single shot... last day long" formulation.
Manu Chaudhry, Joint Managing Director of the company on the occasion said, "This novel formulation based on NDDS (Novel Drug Delivery System) technology will fill in the gap in supply of better pain relief therapies, especially for the aged population. It is not only going to reduce the number of pricks but will also drastically reduce the side effects associated with the use of Nonsteroidal anti-inflammatory drugs (NSAID)."
Discussing the benefits of the drug, Chaudhary added, "ACHNIL acts directly by giving instant relief from acute pain and is effective for the next 24 hours against the conventional daily dose of three injections of diclofenac given every eight hours."
The marketing team of Venus is fully geared for a country wide launch. "The Indian market for pain management is approximately Rs 2000 crore which is growing at the rate of 16 per cent to 20 per cent annually and is expected to be of Rs 3500 crore by 2015. Venus is expecting a substantial increase in market share in the coming years" said Peeyush Jain, Deputy Managing Director and head of marketing, Venus. It also plans to launch ACHNIL in other markets worldwide.
